Furthermore, 40.4% of ICSRs involved hospitalized patients, 2.7% resulted in patient mortality, 0.9% led to disability, and 2.8% caused life-threatening reactions, while only 1.7% classified as non-serious outcomes
This also affects the stroma, in reducing both angiogenesis as well as possibilities of immune escape by tumour cells
According to the MHRA-approved Summary of Product Characteristics (SmPC), nausea is very common (affecting more than 1 in 10 people), while abdominal pain, vomiting, diarrhoea, and constipation are common (affecting between 1 in 100 and 1 in 10 people)
If you are comfortable with compounded semaglutide from a credentialed pharmacy, continue to Question 3